

Lionel Hebbard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5791258/publications.pdf>

Version: 2024-02-01

53
papers

2,392
citations

172457

29
h-index

206112

48
g-index

53
all docs

53
docs citations

53
times ranked

4902
citing authors

#	ARTICLE	IF	CITATIONS
1	Cell adhesion an important determinant of myogenesis and satellite cell activity. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2022, 1869, 119170.	4.1	8
2	Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data. <i>Seminars in Cancer Biology</i> , 2022, 86, 799-815.	9.6	28
3	The role of DNA damage and repair in liver cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188493.	7.4	23
4	An aptamer-based drug delivery agent (CD133-apt-Dox) selectively and effectively kills liver cancer stem-like cells. <i>Cancer Letters</i> , 2021, 501, 124-132.	7.2	38
5	Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma. <i>Biomedicines</i> , 2021, 9, 1639.	3.2	84
6	The effects of fructose and metabolic inhibition on hepatocellular carcinoma. <i>Scientific Reports</i> , 2020, 10, 16769.	3.3	7
7	Independent regulation of tumorigenesis and fibrosis in non-alcoholic fatty liver disease. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 106-108.	1.5	0
8	A Sweet Connection? Fructose's Role in Hepatocellular Carcinoma. <i>Biomolecules</i> , 2020, 10, 496.	4.0	11
9	The Role of Micronutrients in the Infection and Subsequent Response to Hepatitis C Virus. <i>Cells</i> , 2019, 8, 603.	4.1	46
10	Targeting mTOR and Src restricts hepatocellular carcinoma growth in a novel murine liver cancer model. <i>PLoS ONE</i> , 2019, 14, e0212860.	2.5	18
11	The role of obesity in inflammatory bowel disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 63-72.	3.8	34
12	A novel function for HEG1 in promoting metastasis in hepatocellular carcinoma. <i>Clinical Science</i> , 2019, 133, 2019-2022.	4.3	6
13	Aptamers as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers. <i>Advanced Drug Delivery Reviews</i> , 2018, 134, 107-121.	13.7	63
14	The role of AdipoR1 and AdipoR2 in liver fibrosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 700-708.	3.8	25
15	A novel role for polymeric immunoglobulin receptor in tumour development: beyond mucosal immunity and into hepatic cancer cell transformation. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 52-55.	1.5	6
16	Overcoming treatment resistance in cancer: Current understanding and tactics. <i>Cancer Letters</i> , 2017, 387, 69-76.	7.2	35
17	Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors. <i>Cancer Letters</i> , 2017, 390, 188-200.	7.2	30
18	Adiponectin confers protection from acute colitis and restricts a B cell immune response. <i>Journal of Biological Chemistry</i> , 2017, 292, 6569-6582.	3.4	32

#	ARTICLE	IF	CITATIONS
19	Aptamer-Based Therapeutic Approaches to Target Cancer Stem Cells. <i>Theranostics</i> , 2017, 7, 3948-3961.	10.0	51
20	Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells. <i>Molecular Cancer</i> , 2017, 16, 165.	19.2	143
21	Implementing genetic screening for the management of hepatic disease. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 359-362.	1.5	1
22	The functional roles of T-cadherin in mammalian biology. <i>AIMS Molecular Science</i> , 2017, 4, 62-81.	0.5	9
23	Aptamers: A promising chemical antibody for cancer therapy. <i>Oncotarget</i> , 2016, 7, 13446-13463.	1.8	82
24	Molecular cross-talk between the liver and white adipose tissue links excessive nutrition to hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2016, 5, S1222-S1226.	1.0	5
25	Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play. <i>World Journal of Gastroenterology</i> , 2016, 22, 2494.	3.3	45
26	Editorial (Thematic Issue: Gene Therapy for Gastrointestinal and Liver Cancers: Past Experience,) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 40</i>	2.0	0
27	Editorial (Thematic Issue: Induced Pluripotent Stem Cells (iPSCs) in the Gastroenterology and) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 40</i> 2015, 10, 190-192.	1.3	0
28	Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion. <i>Journal of Biological Chemistry</i> , 2015, 290, 5533-5542.	3.4	50
29	The role of fructose in metabolism and cancer. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2015, 22, 79-89.	0.7	42
30	Effect of resveratrol on experimental non-alcoholic steatohepatitis. <i>Pharmacological Research</i> , 2015, 95-96, 34-41.	7.1	33
31	Oct4 is a reliable marker of liver tumor propagating cells in hepatocellular carcinoma. <i>Discovery Medicine</i> , 2015, 20, 219-29.	0.5	21
32	Non-alcoholic steatohepatitis weakens the acute phase response to endotoxin in rats. <i>Liver International</i> , 2014, 34, 1584-1592.	3.9	13
33	Non-viral causes of liver cancer: Does obesity led inflammation play a role?. <i>Cancer Letters</i> , 2014, 345, 223-229.	7.2	62
34	Multifaceted roles of Adiponectin in cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 59-69.	4.7	74
35	Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, G295-G301.	3.4	44
36	Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells. <i>Cancer Letters</i> , 2014, 351, 232-241.	7.2	39

#	ARTICLE	IF	CITATIONS
37	Embelin Reduces Colitis-Associated Tumorigenesis through Limiting IL-6/STAT3 Signaling. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1206-1216.	4.1	59
38	Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. <i>World Journal of Gastroenterology</i> , 2014, 20, 16464.	3.3	40
39	Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro. <i>Cancer Letters</i> , 2013, 341, 224-230.	7.2	50
40	1301 ENDOTOXIN CAUSES HIGH MORTALITY AND REDUCED HEPATIC SYNTHESIS OF ACUTE PHASE PROTEINS IN RATS WITH EXPERIMENTAL NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Hepatology</i> , 2013, 58, S525.	3.7	0
41	Hepatic fat loss in advanced nonalcoholic steatohepatitis: Are alterations in serum adiponectin the cause?. <i>Hepatology</i> , 2013, 57, 2180-2188.	7.3	136
42	ROCK1 Inhibition Promotes the Self-Renewal of a Novel Mouse Mammary Cancer Stem Cell. <i>Stem Cells</i> , 2013, 31, 12-22.	3.2	28
43	Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD. <i>Current Pharmaceutical Design</i> , 2013, 19, 5280-5296.	1.9	0
44	Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD. <i>Current Pharmaceutical Design</i> , 2013, 19, 5280-96.	1.9	5
45	Role of adiponectin and its receptors in cancer. <i>Cancer Biology and Medicine</i> , 2012, 9, 213-20.	3.0	42
46	Animal models of nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 35-44.	17.8	399
47	Control of mammary tumor differentiation by SKI-606 (bosutinib). <i>Oncogene</i> , 2011, 30, 301-312.	5.9	25
48	The chicken or the egg: Adipocytes and hepatic insulin resistance. <i>Hepatology</i> , 2010, 51, 1076-1079.	7.3	1
49	Maternal Embryonic Leucine Zipper Kinase Is Upregulated and Required in Mammary Tumor-Initiating Cells <i>in vivo</i> . <i>Cancer Research</i> , 2010, 70, 8863-8873.	0.9	75
50	Hepatitis C Virus Induces the Cannabinoid Receptor 1. <i>PLoS ONE</i> , 2010, 5, e12841.	2.5	46
51	Adiponectin Deficiency Limits Tumor Vascularization in the MMTV-PyV-mT Mouse Model of Mammary Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 3256-3264.	7.0	78
52	T-cadherin Supports Angiogenesis and Adiponectin Association with the Vasculature in a Mouse Mammary Tumor Model. <i>Cancer Research</i> , 2008, 68, 1407-1416.	0.9	154
53	Angiogenic Acceleration of Neu Induced Mammary Tumor Progression and Metastasis. <i>Cancer Research</i> , 2004, 64, 169-179.	0.9	46